Pseudolaric acid B activates PPARα and the phospholipase C (PLC) signaling pathway. Stimulates peroxisomal fatty acyl-CoA oxidase activity. These effects can be blocked by staurosporine. Pseudolaric acid B exhibits significant cytotoxic activities against numerous tumor cell lines. Pseudolaric acid B binds Tubulin, inhibits angiogenesis, reduces HIF-1α protein levels, induces apoptosis, and is an antifungal.
Pseudolaric Acids from Pseudolarix kaempferi: B.N. Zhou, et al.; Planta Med. 47, 35 (1983) The cytotoxic principles of Pseudolarix kaempferi: pseudolaric acid-A and -B and related derivatives: D.J. Pan, et al.; Planta Med. 56, 383 (1990) Antifungal evaluation of pseudolaric acid B, a major constituent of Pseudolarix kaempferi: E. Li, et al.; J. Nat. Prod. 58, 57 (1995) Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists: M.S. Jardat, et al.; Planta Med. 68, 667 (2002) Five new diterpenoids from Pseudolarix kaempferi: S.P. Yang, et al.; J. Nat. Prod. 65, 1041 (2002) Antifungal diterpenoids of Pseudolarix kaempferi, and their structure-activity relationship study: S.P. Yang, et al.; Bioorg. Med. Chem. 11, 4577 (2003) Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect: W.F. Tan, et al.; Eur. J. Pharmacol. 499, 219 (2004) Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1alpha by promoting proteasome-mediated degradation: M.H. Li, et al.; Clin. Cancer Res. 10, 8266 (2004) Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells: X.F. Gong, et al.; Arch. Pharm. Res. 28, 68 (2005) Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo: V.K. Wong, et al.; Clin. Cancer Res. 11, 6002 (2005) Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis: K.S. Li, et al.; World J. Gastroenterol. 11, 7555 (2005) Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin: Y.G. Tong, et al.; Mol. Pharmacol. 69, 1226 (2006) Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death: X. Gong, et al.; Exp. Mol. Med. 38, 428 (2006) Studies on anti-tumour activities of pseudolaric acid-B (PLAB) and its mechanism of action: B. Liu, et al.; J. Asian Nat. Prod. Res. 8, 241 (2006) Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene: J.K. Ko, et al.; Eur. J. Pharmacol. 559, 1 (2007) Structural modification of an angiogenesis inhibitor discovered from traditional chinese medicine and a structure-activity relationship study: S.P. Yang, et al.; J. Med. Chem. 51, 77 (2008)
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.